Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Bad News for Xeljanz Could Affect Pfizer's Fortunes

TheMotleyFool

0 0

How Bad News for Xeljanz Could Affect Pfizer's Fortunes

Pfizer (NYSE: PFE) has enjoyed plenty of good news lately with its successful COVID-19 vaccine. However, the big drugmaker recently announced disappointing results from a post-marketing safety study of autoimmune disease drug Xeljanz. In this Motley Fool Live video recorded on Feb. 3, 2021, Fool.com contributors Keith Speights and Brian Orelli discuss how the bad news for Xeljanz could affect Pfizer's fortunes.

Source Fool.com

Like: 0

PFE

Share